Stay updated with breaking news from Chris Min. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Good morning, and welcome to Longeveron's call today to discuss the company's 2023 First Quarter and Financial Results. All participants are currently in listen-only mode.
12.05.2023 - - New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome; Data reinforce potential mortality benefit - - First patient dosed in Phase 2 clinical trial of Lomecel-BTM for Aging-Related Frailty ...
Operator: Good morning, and welcome to Longeveron's call today to discuss the company's 2022 Fourth Quarter and Full Year Financial Results.
19.01.2023 - - Full results published in European Heart Journal Open - - Study met primary safety endpoint - - All patients alive, transplant-free, and maintained expected rate of growth one year after treatment - - Data supports ongoing clinical ... Seite 1
– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty in Japan in 1Q23 – – Extended cash runway into 2H24 – ...